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DEAR COLLEAG U E :
The Diabetes Prevention and Control Program of the Massachusetts Department of Public Health and members of the  
Diabetes Guidelines Work Group are pleased to present the latest update to the Massachusetts Guidelines for Adult  
Diabetes Care.
First created in 1999, the Guidelines are based on the Clinical Practice Recommendations of the American Diabetes  
Association (ADA), and are revised every two years. Our initial goals were to: 1) develop uniform guidelines that apply  
to adults with diabetes regardless of insurer; 2) help eliminate any confusion brought about by differences in guidelines  
disseminated by individual third party payers; and 3) assist health care professionals in systematizing the care provided  
to people with diabetes. It has always been our goal to create a document that is user-friendly and which would serve as  
a valuable tool to improve diabetes care in the Commonwealth. Over time, we’ve received feedback about making the  
Guidelines even more accessible and user-friendly. This feedback, in addition to the limited number of revisions necessary  
in the past two years, has prompted a change to the format of the 2011 document.
The Massachusetts Adult Diabetes Guidelines: 2011 Executive Summary of Revisions and Recommendations (2011 Executive 
Summary) is intended to serve as an amendment to the 2009 Massachusetts Guidelines for Adult Diabetes Care (2009  
Guidelines). The 2011 Executive Summary highlights the key recommendations for each subsection of the 2009 Guidelines,  
even in instances where no new recommendations exist. In this way, we hope that this document will serve as a complete  
but streamlined reference for evidence-based practice recommendations. We invite you to refer to the 2009 Guidelines for  
a more extensive review of the literature supporting the existing recommendations. 
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We continue to grade evidence for our recommendations 
and revisions based on the grading system developed  
by the ADA. The level of supportive evidence is noted in 
parentheses after each recommendation using the letters  
A, B, C, or E:
(A):  Clear evidence from well-conducted, generalizable,  
randomized controlled trials. 
(B):  Supportive evidence from well-conducted cohort  
studies. 
(C):  Supportive evidence from poorly-controlled or  
uncontrolled studies. 
(E): Expert consensus or clinical experience.
Recommendations with an “A” rating are based on large 
well-designed clinical trials or well-done meta-analyses. 
Generally, these recommendations have the best chance of  
improving outcomes when applied to the population to 
which they are appropriate. Recommendations with lower 
levels of evidence may be equally important but are not  
as well supported. Expert opinion (E) is a separate category  
for recommendations in which there is as yet no evidence 
from clinical trials, in which clinical trials may be impractical, 
or in which there is conflicting evidence.1
•  GUIDELINES FOR ADULT DIABETES CARE LAMINATED SUMMARY:  
This summary of the Guidelines highlights basic medical care for people with diabetes. We suggest you post a summary in 
each exam room as a reminder of recommendations for care.
•  DIABETES CARE CARD (PATIENT WALLET CARD):  
The Diabetes Care Card allows people to track their diabetes care and personal goals. The wallet card has space to record test 
results and services received over four visits. Encourage your patients to bring this card to each office appointment.
•  DETERMINING BODY MASS INDEX (BMI):  
Obesity substantially raises the risk of morbidity from type 2 diabetes and other diseases. The BMI describes relative weight 
for height and is significantly correlated with total body fat content. The BMI may be used to assess overweight and obesity 
and to monitor changes in body weight. http://www.maclearinghouse.com/CatalogDiabetes.htm
•  FLOW SHEET FOR DIABETES CARE:  
The flow sheet reflects the recommendations found on the Guidelines for Adult Diabetes Care laminated summary. It may 
be downloaded for use in your practice and included in patients’ charts. Diabetes medications, exams, and test results can be 
documented over time to track diabetes management. http://www.maclearinghouse.com/CatalogDiabetes.htm
The 2011 Executive Summary has been a cooperative effort among many partners. This unique collaboration eliminates  
the confusion brought about by slight differences in guidelines developed by each managed care organization. This document 
is not intended to serve as a description of benefits or coverage; coverage may vary by insurer. We would like to take this  
opportunity to acknowledge the partners involved in the development of the 2011 Executive Summary:
•  Baystate Health 
•  Blue Cross Blue Shield of Massachusetts
•  Boston Medical Center HealthNet Plan
•  Fallon Community Health Plan
•  Harvard Pilgrim Health Care
•  Health New England
•  Joslin Diabetes Center
•  Massachusetts College of Pharmacy and Health Sciences 
•  Massachusetts Department of Public Health 
•  Massachusetts League of Community Health Centers
•  Massachusetts Medical Society
•  Masspro
•  Neighborhood Health Plan
•  Network Health
•  Partners/MGH
•  Primary Care Clinician (PCC) Plan
•  Tufts Health Plan
•  University of Massachusetts, Amherst 
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The 2011 Executive Summary and the 2009 Guidelines may be downloaded from the Massachusetts Health Promotion  
Clearinghouse at: http://www.maclearinghouse.com/CatalogDiabetes.htm
The ADA’s 2011 Standards of Medical Care in Diabetes are available at: 
http://care.diabetesjournals.org/content/34/Supplement_1/S11.full.pdf+html
In addition to the 2011 Executive Summary and the 2009 Guidelines, the following tools may be ordered or downloaded  
through the Clearinghouse:
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If you have questions about the 2011 Executive Summary or the 2009 Guidelines, please call the Massachusetts Diabetes 
Prevention and Control Program at (617) 624–5070. We invite you to join our efforts to reduce the burden of diabetes in 
Massachusetts by reviewing the 2011 Executive Summary and applying the key recommendations to your practice.
Sincerely, 
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I .   CR ITER IA  FOR THE  D IAG NOSIS  OF  D IAB ET ES  AND  P RED IAB ET ES
For a diagnosis of diabetes, results should be confirmed by repeat testing. If two different tests are  
both above the diagnostic thresholds, the diagnosis of diabetes is confirmed. A confirmatory test is  
not required when results fall into the prediabetes range. 
* It is the opinion of the Work Group that patients with random glucose > 200 mg/dl, even if asymptomatic, do not require 
further diagnostic testing, as long as there are no other mitigating factors that would induce reversible hyperglycemia  
(e.g., glucocorticoids, and/or recent physiological stress).
The recommendations have been updated to include the 
use of the A1C test for diagnosing diabetes and prediabetes.  
In 2010, the American Diabetes Association (ADA)  
endorsed the recommendation of an international expert 
committee to include the use of the A1C test to diagnose 
diabetes, with a threshold of ≥ 6.5%. The recommendation 
has also been endorsed with qualifications by the American 
Association of Clinical Endocrinologists/American College 
of Endocrinologists, and the Endocrine Society. While the 
fasting blood sugar remains the preferred diagnostic test for 
diagnosing diabetes, the two-hour oral glucose tolerance 
(OGTT) or A1C tests are also acceptable. 
The A1C test has several advantages over the fasting plasma 
glucose (FPG) test, including greater convenience, since 
fasting is not required, and fewer day-to-day variations. 
These advantages must be balanced against the A1C test’s 
greater cost and the incomplete correlation between A1C 
and average glucose in certain individuals; A1C may not 
be as accurate in non-Caucasian individuals and in patients 
with certain forms of anemia and hemoglobinopathies. 
Also, the A1C cut point of ≥ 6.5% identifies one-third 
fewer cases of undiagnosed diabetes than a fasting glucose 
cut point of ≥ 126 mg/dl.2, 3, 4, 5
1     |     MASSACHUSETTS  ADULT  D I ABETES  G UI DEL I NES :  2011 Executive Summary of Revisions and Recommendations
Criteria for the Diagnosis of Diabetes and Prediabetes
TEST DIABETES PREDIABETES
A1C > 6.5% 5.7–6.4%
FPG > 126 mg/dl 100–125 mg/dl
2–h 75 g OGTT > 200 mg/dl 140–199 mg/dl
Random plasma glucose > 200 mg/dl with classic  N/A
    symptoms of hyperglycemia* 
I I .    CR ITER IA  FOR TE ST ING FOR D IAB ET ES  AND  P RED IAB ET ES  
IN  ASYMPTOMATIC  ADU LTS
Although preventive screening is widely recognized as a 
key component of cost-effective, high-quality health care, 
screening for diabetes falls short of the U.S. Preventive 
Services Task Force recommendations. In 2007, only 64% 
of Massachusetts residents with risk factors for diabetes 
reported being screened in the last three years.6 
Periodic screening of high-risk individuals as part of  
ongoing medical care will identify people with undiagnosed  
diabetes and prevent diabetes-related complications through 
earlier treatment.
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Criteria for Testing for Diabetes and Prediabetes in Asymptomatic Adults
Testing to detect type 2 diabetes and assess risk for future diabetes in asymptomatic people should be considered 
in adults of any age who are overweight or obese (BMI > 25 kg/m2 or BMI > 23 kg/m2 for Asian individuals) AND 
who have one or more of the following additional risk factors for diabetes:
	 •	 Habitually	physically	inactive
	 •	 First-degree	relative	with	type	2	diabetes
	 •	 	Members	of	a	high-risk	ethnic	population	(African	American,	Latino,	Native	American,	Asian	American,	 
Pacific Islander)
	 •	 	Women	who	have	delivered	a	baby	weighing	>	9	lbs.	or	have	been	diagnosed	with	gestational	diabetes	 
mellitus	(GDM)
	 •	 Hypertension	(blood	pressure	>	140/90	mmHg,	or	on	therapy	for	hypertension)
	 •	 High-density	lipoprotein	(HDL)	cholesterol	level	<	35	mg/dl	and/or	a	triglyceride	level	>	250	mg/dl
	 •	 Polycystic	ovarian	syndrome	(PCOS)
	 •	 A1C	>	5.7%,	Impaired	Glucose	Tolerance	(IGT)	or	Impaired	Fasting	Glucose	(IFG)	on	previous	testing
	 •	 Other	conditions	associated	with	insulin	resistance	(e.g.,	acanthosis	nigricans)
	 •	 History	of	vascular	disease
	 •	 A	waist	circumference	>	102	cm	(40”)	for	men	and	>	88	cm	(35”)	for	women
	 •	 Medication	use	that	may	predispose	to	diabetes	(e.g.,	steroids,	atypical	antipsychotics,	protease	inhibitors)
If results are normal, testing should be repeated at three-year intervals, with more frequent testing depending  
on initial results and risk status.
In those individuals without these risk factors, testing should begin at age 45 years. (B)
Recommendations for the Prevention or Delay of Type 2 Diabetes
•	 	Patients	with	IGT	(A),	IFG	(E),	or	an	A1C	5.7–6.4%	(E) should be referred to an effective ongoing support  
program	to	achieve	a	7%	weight	loss	and	for	increasing	physical	activity	to	at	least	150	minutes	per	week	of	 
moderate	activity	such	as	walking.
•	 	Follow-up	counseling	appears	to	be	important	for	success.	(B) 
•	 	In	addition	to	lifestyle	counseling,	metformin	may	be	considered	in	those	individuals	at	highest	risk	for	 
developing	diabetes,	such	as	those	with	multiple	risk	factors,	especially	if	they	demonstrate	progression	of	 
hyperglycemia	(i.e.,	A1C	>	6%)	despite	lifestyle	interventions.	(B)
•	 	Monitoring	for	the	development	of	diabetes	in	those	individuals	with	prediabetes	should	be	performed	 
every year. (E)
I I I .   CLASS IF IC AT ION OF  D IABETES
IV.   PREVENTION OR DE LAY OF  T YPE  2  D IAB ETES
GESTATIONAL DIABETES MELLITUS
Women identified with undiagnosed type 2 diabetes at  
the initial prenatal visit, using standard diagnostic criteria 
(FPG, 2-hour 75 g OGTT, or A1C), should receive a  
diagnosis of type 2 diabetes, not gestational diabetes.
PREDIABETES
In addition to IFG (FPG 100–125 mg/dl) and IGT  
(2-hr 75 g OGTT 140–199 mg/dl), an A1C range of 
5.7–6.4% has been included as a category of increased  
risk for future diabetes.
Recommendations have been updated to include individuals  
with an A1C between 5.7 and 6.4% in the at-risk group 
and to consider metformin for individuals at highest risk for 
developing diabetes, such as those with multiple risk factors, 
especially if they demonstrate progression of hyperglycemia. 
The Centers for Disease Control and Prevention (CDC) 
established the National Diabetes Prevention Program  
to provide training, program recognition, implementation 
support, and marketing for community-based lifestyle  
intervention programs for preventing type 2 diabetes: 
http://www.cdc.gov/diabetes/projects/prevention_ 
program.htm.
3     |     MASSACHUSETTS  ADULT  D I ABETES  G UI DEL I NES :  2011 Executive Summary of Revisions and Recommendations
V.    TREATMENT APPROAC H PR INCIPL ES
Optimal glycemic control is fundamental to the management 
of diabetes. In addition to lifestyle management,  
pharmacologic therapy is necessary for most people with 
type 2 diabetes to achieve glycemic goals. An A1C goal of 
< 7% is reasonable for many non-pregnant adults. When 
setting treatment goals for individuals with type 2 diabetes, 
it is important to assess the risk for severe hypoglycemia and 
consider the person’s ability to comprehend the regimen. 
Consider as well other factors that may influence the  
treatment’s benefit, including advanced age, end-stage  
renal disease (ESRD), advanced cardiovascular or  
cerebrovascular disease, or other comorbidities that may 
lead to a reduced life span. 
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Recommendations for Glycemic Goals
Points to Remember When Setting Glycemic Goals
•	 	Perform	the	A1C	test	at	least	two	times	a	year	in	patients	who	are	meeting	treatment	goals	and	who	have	 
stable glycemic control. (E)
•	 	Perform	the	A1C	test	quarterly	in	patients	whose	therapy	has	changed	or	who	are	not	meeting	glycemic	 
goals. (E)
•	 	A	lower	A1C	is	associated	with	lower	rates	of	microvascular	complications;	however,	there	is	a	greater	risk	 
of hypoglycemia. For patients with frequent or severe hypoglycemia, less intensive glycemic control may  
be preferable.
•	 If	preprandial	glucose	goals	are	within	target,	but	A1C	values	are	still	not	optimal,	target	postprandial	glucose.
•	 Children,	pregnant	women,	and	elderly	individuals	require	special	consideration	when	setting	glycemic	goals.
•	 Avoid	rapid	decline	in	glycemia	when	prior	adverse	control	was	substantial	or	prolonged.
No changes have been made to the recommendations for 
glycemic goals. 
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VI .    D IABETES  S E LF-MANAGE MENT ED UCAT ION (DSME)  
AND MEDIC AL  NU TRIT ION TH ERAPY (MNT) 
Although both DSME and MNT have been demonstrated 
to improve glycemia and CVD risk,7, 8, 9 these services 
remain underutilized. The overall objectives of DSME are 
to support informed decision-making, self-care behaviors, 
problem-solving, and active collaboration with the health 
care team to improve clinical outcomes.  
DSME is a specialized session of classes designed to help  
people with diabetes successfully manage their disease. DSME 
consists of 10 hours of initial training from an accredited 
education program and an additional two hours of follow-
up training each year thereafter with a prescription from  
a health care provider. National standards regarding what 
is included in DSME classes are defined by the American 
Diabetes Association (ADA) and the American Association 
of Diabetes Educators (AADE).10, 11
MNT is provided by a registered dietitian and is distinct 
from DSME. MNT involves the development of a personal-
ized healthy eating plan for individuals with prediabetes  
and diabetes. It includes an in-depth nutrition assessment 
and nutrition counseling with a focus on achieving positive  
outcomes for normalizing A1C, serum lipids, and blood 
pressure. MNT consists of three hours of one-on-one 
counseling services the first year, and two hours each year 
thereafter with the possibility of additional hours of  
treatment with a physician’s referral.12
Recommendations for Diabetes Self-Management Education
Recommendations for Medical Nutrition Therapy
People	with	diabetes	should	receive	DSME	according	to	national	standards	at	the	time	of	diagnosis	and	as	 
needed thereafter. (B)
•	 	Individuals	with	prediabetes	or	diabetes	should	receive	individualized	MNT	as	needed	to	achieve	treatment	 
goals. (B)
•	 	Weight	loss	is	recommended	for	all	overweight	or	obese	individuals	who	have	or	who	are	at	risk	for	diabetes.	(A)
•	 	For	weight	loss,	either	low-carbohydrate	or	low-fat,	calorie-restricted	diets	may	be	effective	in	the	short	term	 
(up	to	one	year).	(A)
•	 	For	patients	on	low-carbohydrate	diets,	monitor	lipid	profiles,	renal	function,	and	protein	intake	(in	those	with	
nephropathy) and adjust hypoglycemic therapy as needed. (E)
No changes have been made to the recommendations for 
DSME and MNT. 
Recommendations for Physical Activity
•	 	People	with	diabetes	should	be	advised	to	perform	at	least	150	minutes/week	of	physical	activity	 
(50–70%	of	maximum	heart	rate).	(A)
•	 	In	the	absence	of	contraindications,	people	with	type	2	diabetes	should	be	encouraged	to	perform	 
resistance	training	three	times	per	week;	targeting	all	major	muscle	groups.	(A)
VI I .   PHYS ICAL  AC T IV ITY
VI I I .   PHARMACOLOG IC AL  THE RAPY
IX .   CARDIOVAS C U LAR R IS K-RED UCT ION GUID EL INES
There are a number of pharmacologic agents and strategies 
that can be employed to reach treatment goals. Emphasis 
should be on modalities of therapy that have been  
demonstrated to reduce morbidity and prolong life. When 
choosing therapy, as long as treatment goals can be reached 
with safe and effective options, it is less important what 
those therapies are. The decision of which agent to use 
Cardiovascular disease (CVD) is the major cause of morbidity 
and mortality for people with diabetes. Hypertension and 
dyslipidemia, common coexisting conditions, are clear risk 
factors for CVD and diabetes itself confers independent risk. 
should depend on the degree of A1C-lowering desired and 
the expected decline in A1C for each class of medication,  
as well as the effects of the medication on weight and lipid  
profiles, contraindications, side effects, cost, and potential  
degree of adherence to the regimen (See Table of Commonly  
Used Anti-hyperglycemic Agents: http://www.maclearing 
house.com/CatalogDiabetes.htm). 
Controlling individual cardiovascular risk factors is a major 
component of the prevention and management of CVD in 
people with diabetes. 
No changes have been made to the recommendations for 
physical activity. 
People should be encouraged to be more active. Some 
physical activity is better than none and adults who  
participate in any amount of physical activity gain some 
health benefits. Even if patients are not able to meet  
the physical activity recommendations above, mild to  
moderate activity should be encouraged at all levels  
and abilities. This can be accomplished by building  
activity into the daily routine, such as using stairs rather 
than an elevator, and by slowly increasing the amount  
of time engaged in physical activity. 
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A. HYPERTENSION
Recommendations for control of hypertension have been 
revised to reflect new evidence reinforcing the importance 
of individualization of blood pressure goals. The ACCORD 
Blood Pressure Trial evaluated the effect of targeting a  
systolic blood pressure of 120 mmHg, as compared with a 
goal of 140 mmHg, among patients with type 2 diabetes  
at high risk for cardiovascular events. 
The results provide no evidence that the strategy of intensive 
blood pressure control reduces the rate of a composite  
outcome of fatal and nonfatal major cardiovascular events. 
Additionally, the rate of serious adverse effects of treatment 
such as hypotension and hyperkalemia were significantly 
higher in the intensive control group.14
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Recommendations for Controlling Hypertension
•	 	A	goal	systolic	blood	pressure	(SBP)	<	130	mmHg	is	appropriate	for	most	patients	with	diabetes.	(C)  
Based	on	patient	characteristics	and	response	to	therapy,	higher	or	lower	systolic	blood	pressure	targets	may	 
be appropriate. (B)
•	 Patients	with	diabetes	should	be	treated	to	a	diastolic	blood	pressure	(DBP)	<	80	mmHg.	(B) 
•	 	Patients	with	SBP	of	130–139	mmHg	or	DBP	of	80–89	mmHg	may	be	given	lifestyle	therapy	alone	for	a	maximum	
of three months and then, if targets are not achieved, be treated with the addition of pharmacological agents. (E)
•	 	Patients	with	more	severe	hypertension	(SBP >	140	mmHg	or	DBP	>	90	mmHg)	at	diagnosis	or	follow-up	should	
receive	prescriptions	for	both	antihypertensive	medication	and	lifestyle/behavioral	changes.	(A)
•	 	All	patients	with	diabetes	and	hypertension	should	be	treated	with	angiotensin-converting	enzyme	(ACE)	 
inhibitors.	If	ACE	inhibitors	are	not	tolerated,	an	angiotensin	II	receptor	blocker	(ARB)	should	be	considered,	if	
not	contraindicated.	Add	a	thiazide	diuretic	in	those	with	estimated	GFR	>	30	ml/min	per	1.73	m2 or a loop  
diuretic	for	those	with	estimated	GFR	<	30	ml/min	per	1.73	m2 if needed to reach target blood pressure. (C)
•	 Monitor	renal	function	and	serum	potassium	levels	when	using	ACE	inhibitors,	ARBs,	or	diuretics.	(E)
•	 	Multiple	drug	therapy	utilizing	two	or	more	agents	at	proper	doses	is	often	necessary	to	reach	target	levels.	(A)
•	 	Clinical	trials	provide	evidence	that	ACE	inhibitors	and	ARBs	have	an	additional	impact	on	nephropathy	 
and	CVD.	(A)
•	 	Beta-blockers	should	be	added	for	those	who	have	had	a	recent	myocardial	infarction	(MI)	if	not	contraindicated;	
caution should be used in those with hypoglycemia unawareness. (A)
•	 	In	pregnant	patients	with	diabetes	and	chronic	hypertension,	target	blood	pressure	goals	of	110–129/65–79	mmHg	
are	suggested.	ACE	inhibitors	and	ARBs	are	contraindicated	during	pregnancy	and	should	be	discontinued	in	
women planning pregnancy due to their teratogenic effects. (E)
Recommendations for Dyslipidemia/Lipid Management
•	 	In	most	adult	patients,	measure	fasting	test	for	lipid	disorders	at	least	annually	with	more	frequent	testing	as	 
necessary to reach goal levels. (E)
•	 	Testing	every	two	years	is	adequate	for	those	with	low-density	lipoprotein	(LDL),	high-density	lipoprotein	(HDL),	
and	triglycerides	(TG)	within	the	target	levels.	(E)
•	 	Lifestyle	modification	with	MNT	focusing	on	reduction	of	saturated	fat,	trans	fat,	and	cholesterol	intake;	increased	
intake	of	foods	rich	in	omega-3	fatty	acids,	viscous	fiber,	and	plant	sterols;*	weight	loss	(if	indicated);	and	 
increased physical activity should be recommended to improve lipid profile. (A)
•	 	Statin	therapy	should	be	added	to	lifestyle	therapy,	regardless	of	baseline	lipid	levels,	for	patients	with	diabetes	
with	overt	CVD	(A)	and	for	patients	without	CVD	who	are	over	the	age	of	40	and	have	one	or	more	other	CVD	
risk	factors.	(A)
•	 	In	patients	without	overt	CVD	and	under	age	40,	or	those	with	multiple	CVD	risk	factors,	statin	therapy	should	
be	considered	in	addition	to	lifestyle	therapy	if	LDL	cholesterol	remains	above	100	mg/dl.	(E)
•	 In	individuals	without	overt	CVD,	the	primary	goal	is	an	LDL	cholesterol	of	<	100	mg/dl.	(A)
•	 	In	individuals	with	overt	CVD,	a	lower	LDL	cholesterol	goal	of	<	70	mg/dl,	using	a	high	dose	of	a	statin,	is	an	 
option. (B)
•	 	If	patients	treated	with	drugs	do	not	reach	targets	on	maximal	tolerated	statin	therapy,	a	reduction	in	LDL	 
cholesterol of ~30–40%	from	baseline	is	an	alternative	therapeutic	goal.	(A)
•	 	Triglyceride	levels	<	150	mg/dl	and	HDL	cholesterol	>	40	mg/dl	in	men	and	>	50	mg/dl	in	women	are	desirable.	
However,	LDL	cholesterol-targeted	statin	therapy	remains	the	preferred	strategy.	(C)
•	 Statin	therapy	is	contraindicated	in	pregnancy.	(E)
* Omega-3 fatty acids are usually found in seafood, such as salmon, herring, sardines, and mackerel. They can also be found in flaxseeds, flaxseed oil, and walnuts. 
* Examples of soluble or viscous fibers include oat bran, oatmeal, beans, peas, rice bran, barley, citrus fruits, strawberries, and apple pulp. 
* Plant sterols are naturally found in fruits, vegetables, whole grains, legumes, nuts, and seeds. 
B. DYSLIPIDEMIA/LIPID MANAGEMENT 
The recommendations have been revised to include the  
addition of omega-3 fatty acids, viscous fiber, and plant  
sterols to lifestyle modifications. 
The ACCORD lipid arm, in which adults with type 2  
diabetes at high risk for cardiovascular events were given 
either statin monotherapy or combination therapy of  
statin plus fibrate found select subgroups of patients who 
benefitted from combination therapy. However, the overall 
risk of heart attack, stroke, or death from cardiovascular 
disease was not lower than treatment with statins alone. 
At this time, the FDA has made no new conclusions  
or recommendations regarding the combination use of  
simvastatin or other statin drugs and fenofibrate.15 
The FDA is recommending limiting the use of simvastatin 
(80 mg) because of increased risk of muscle damage.  
Simvastatin 80 mg should be used only in patients who 
have been taking this dose for 12 months or more without 
evidence of muscle injury (myopathy). Simvastatin 80 mg 
should not be started in new patients, including patients 
already taking lower doses of the drug.16
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C. ANTIPLATELET THERAPY
This section has been revised to reflect recent trials that 
question the benefit of aspirin therapy for primary cardio- 
vascular disease prevention in moderate- or low-risk patients. 
The recommendation has been changed to consider aspirin 
therapy as a primary prevention strategy in individuals with 
diabetes who are at increased cardiovascular risk (10-year 
risk > 10%). This includes most men over age 50 and  
most women over age 60 who have at least one additional 
risk factor (family history of CVD, hypertension, smoking, 
dyslipidemia, and/or albuminuria). 
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Recommendations for Antiplatelet Therapy
•	 	Use	aspirin	therapy	(75–162	mg/day)	as	a	secondary	prevention	strategy	in	men	and	women	with	diabetes	 
and	a	history	of	myocardial	infarction,	vascular	bypass	procedure,	stroke	or	transient	ischemic	attack,	peripheral	
vascular	disease,	claudication,	and/or	angina.	(A)
•	 	Consider	aspirin	therapy	(75–162	mg/day)	as	a	primary	prevention	strategy	in	men	and	women	with	type	1	or	
type	2	diabetes	at	increased	cardiovascular	risk	(10-year	risk	>	10%).	This	includes	most	men	over	50	years	 
of	age	or	most	women	over	60	years	of	age	who	have	at	least	one	additional	risk	factor	(family	history	of	CVD,	
hypertension,	smoking,	dyslipidemia,	albuminuria).	(C)
•	 	Aspirin	should	not	be	recommended	for	CVD	prevention	for	adults	with	diabetes	who	are	at	low	CVD	risk	 
(10-year	CVD	risk	<	5%),	men	under	50	years	of	age	and	women	under	60	years	of	age	with	no	additional	risk	
factors.	For	patients	in	these	age	groups	with	multiple	other	risk	factors	(i.e.,	10-year	CVD	risk	5–10%),	clinical	
judgment should guide treatment decisions. (C) 
•	 	People	with	aspirin	allergy,	bleeding	tendency,	recent	gastrointestinal	bleeding,	and	clinically	active	hepatic	 
disease	are	not	candidates	for	aspirin	therapy.	Other	antiplatelet	agents,	such	as	clopidogrel,	may	be	a	 
reasonable	alternative	for	high-risk	patients	with	contraindications	to	aspirin	therapy.	(B)
•	 	Combination	therapy	with	aspirin	(75–162	mg/day)	and	clopidogrel	(75	mg/day)	is	reasonable	for	up	to	a	year	
after an acute coronary syndrome. (B)
D. CORONARY HEART DISEASE 
In patients with prior myocardial infarction, recommendations 
on the use of beta-blockers have been revised. Continuation 
of beta-blockers for at least two years after the event is  
recommended, and the level of evidence has been changed 
from level A to level B. 
Longer term use of beta-blockers in the absence of  
hypertension is reasonable if well tolerated, however data  
are lacking. The recommendation for coronary artery  
disease (CAD) screening in asymptomatic patients has  
also been revised. 
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Recommendations for Coronary Heart Disease Screening and Treatment
•	 	In	patients	with	known	CVD:	angiotensin-converting	enzyme	(ACE)	inhibitor	(C), aspirin (A), and statin therapy 
(if	not	contraindicated)	(A),	should	be	used	to	reduce	the	risk	of	cardiovascular	events.
•	 	In	patients	>	40	years	of	age	with	another	cardiovascular	risk	factor	(hypertension,	premature	family	history,	 
dyslipidemia,	microalbuminuria,	cardiac	autonomic	neuropathy,	or	smoking),	aspirin	and	statin	therapy	 
(if	not	contraindicated)	should	be	used	to	reduce	the	risk	of	cardiovascular	events.	(B)
•	 	A	beta-blocker,	if	not	contraindicated,	should	be	added	for	at	least	two	years	for	patients	with	a	prior	 
myocardial infarction. (B)
•	 	Longer	term	use	of	beta-blockers	in	the	absence	of	hypertension	is	reasonable	if	well	tolerated,	however	data	 
are	lacking.	(E)
•	 	Screening	tests	such	as	a	stress	electrocardiogram	(ECG),	and/or	stress	echocardiography,	and/or	perfusion	 
imaging	may	be	beneficial	for	those	with:
  1) 	typical	or	atypical	cardiac	symptoms,	and/or
  2)  an abnormal resting electrocardiogram. (E)
•	 	In	asymptomatic	patients,	routine	screening	for	CAD	is	not	recommended	as	it	does	not	improve	outcomes	 
as	long	as	CVD	risk	factors	are	treated.	(A)
Recommendations for Smoking Cessation
•	 Advise	all	patients	not	to	smoke.	(A) 
•	 	Include	smoking	cessation	counseling	and	other	forms	of	treatment	as	a	routine	component	of	diabetes	care.	(B)
X .   SMOKING C E SSAT ION
No changes have been made to the recommendations for 
smoking cessation. 
QuitWorks is a free smoking cessation referral service  
available to all Massachusetts health care providers that 
links patients who use tobacco to the evidence-based 
tobacco treatment services offered by the Massachusetts 
Smokers’ Helpline (www.quitworks.org). 
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Referring providers receive reports from QuitWorks on the 
Helpline services each patient selects and their subsequent 
quit status.
Recommendations for Nephropathy Screening
Stages of Kidney Disease17 
XI .   NEPHROPATHY
No changes have been made to the recommendations for 
nephropathy screening. This section has been updated to 
include a table of screening and treatment recommendations 
for renal disease.
* Kidney damage is defined as abnormalities on pathologic, urine, blood or imaging tests
•	 Type	2	diabetes:	assess	urine	albumin	excretion	at	diagnosis	and	yearly	thereafter.	(E)
•	 Type	1	diabetes:	assess	urine	albumin	excretion	after	five	years	of	disease	duration	and	yearly	thereafter.	(E)
•	 	Serum	creatinine	should	be	measured	annually	in	all	adults	with	diabetes	for	the	estimation	of	glomerular	 
filtration	rate	(GFR)	and	to	stage	the	level	of	chronic	kidney	disease.	(E)
  
STAGE DESCRIPTION GFR (ml/min per 1.73 m2 body surface area)
1 Kidney damage* with normal or increased GFR > 90
2 Kidney damage* with mildly decreased GFR 60–89
3 Moderately decreased GFR 30–59
4 Severely decreased GFR 15–29
5 Kidney Failure < 15 or dialysis
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Management of Chronic Kidney Disease in Diabetes18 
Microalbuminuria, a low but abnormal level of albumin  
in the urine, is a risk factor for diabetes-related renal and 
cardiovascular complications. Studies have demonstrated 
that multifactorial interventions, including pharmacological  
management of hyperglycemia, hypertension, and  
dyslipidemia, can reduce progression of albuminuria, 
retinopathy, neuropathy, and composite outcomes of CVD 
events or death.19 Continued annual monitoring of urine 
albumin excretion is recommended to assess response  
to therapy and progression of disease.  
All patients	 Yearly	measurement	of	creatinine,	urinary	albumin	excretion,	potassium
GFR 45–60	 •	 	Referral	to	nephrology	if	possibility	for	nondiabetic	kidney	disease	exists	(duration	type	1	
diabetes	<	10	years,	heavy	proteinuria,	abnormal	findings	on	renal	ultrasound,	resistant	 
hypertension,	rapid	fall	in	GFR,	or	active	urinary	sediment)	
	 	 •	 Consider	need	for	dose	adjustment	of	medications
	 	 •	 Monitor	estimated	GFR	(eGFR)	every	six	months
	 	 •	 	Monitor	electrolytes,	bicarbonate,	hemoglobin,	calcium,	phosphorus,	and	parathyroid	 
hormone at least yearly
	 	 •	 Assure	vitamin	D	sufficiency
	 	 •	 Consider	bone	density	testing
	 	 •	 Referral	for	dietary	counseling
GFR 30–44	 •	 	Referral	to	nephrology	if	possibility	for	nondiabetic	kidney	disease	exists	(duration	type	1	
diabetes	<	10	years,	heavy	proteinuria,	abnormal	findings	on	renal	ultrasound,	resistant	 
hypertension,	rapid	fall	in	GFR,	or	active	urinary	sediment)
	 	 •	 Consider	referral	to	nephrologist	if	unable	to	achieve	targets		
	 	 •	 Assure	vitamin	D	sufficiency
	 	 •	 Consider	bone	density	testing
	 	 •	 Consider	need	for	dose	adjustment	of	medications
	 	 •	 Referral	for	dietary	counseling
	 	 •	 Monitor	eGFR	every	three	months		
	 	 •	 	Monitor	electrolytes,	bicarbonate,	calcium,	phosphorus,	parathyroid	hormone,	hemoglobin,	
albumin,	and	weight	every	three	to	six	months	
	 	 •	 Consider	need	for	dose	adjustment	of	medications
GFR < 30	 Referral	to	nephrologist
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GFR 
(ml/min/1.73 m2) RECOMMENDED 
Adapted from the ADA Standards of Medical Care in Diabetes — 2011
Recommendations for Retinopathy Screening and Treatment 
•	 	An	ophthalmologist	or	optometrist	who	is	knowledgeable	and	experienced	in	diagnosing	the	presence	of	 
diabetic	retinopathy	and	is	aware	of	its	management	should	perform	comprehensive	eye	exams.	(E)
•	 	Adults	with	type	1	diabetes	should	have	an	initial	dilated	and	comprehensive	eye	examination	within	five	years	 
of the diagnosis of diabetes. (B)
•	 	Adults	with	type	2	diabetes	should	have	an	initial	dilated	and	comprehensive	eye	examination	shortly	following	
the diagnosis of diabetes. (B)
•	 	Subsequent	examinations	for	patients	with	type	1	and	type	2	diabetes	should	be	repeated	annually.	 
A	qualified	eye	care	professional	may	recommend	less	frequent	exams	(i.e.,	every	two	years).	(B)
•	 Examinations	will	be	required	more	frequently	if	retinopathy	is	progressing.	(B)
•	 	Women	with	preexisting	diabetes	should	have	a	comprehensive	eye	exam	when	planning	pregnancy	and	 
should	be	counseled	on	the	risk	of	development	and/or	progression	of	diabetic	retinopathy.	(B)
•	 	Women	with	diabetes	who	become	pregnant	should	have	a	comprehensive	eye	exam	in	the	first	trimester	 
with	close	follow-up	at	intervals	determined	by	retinopathy	status	throughout	pregnancy	and	for	one	year	 
postpartum. (B)
•	 	Retinal	screening	is	not	necessary	for	women	who	develop	gestational	diabetes	because	these	women	are	 
not	at	increased	risk	for	diabetic	retinopathy.	(B)
•	 	In	general,	small	doses	of	aspirin	for	cardioprotection	are	safe	in	patients	with	retinopathy;	when	in	doubt,	 
consult a diabetic eye disease specialist. (A)
•	 Anyone	with	a	change	or	loss	of	vision	requires	prompt	referral	to	an	eye	care	specialist.	(A)
XI I .   RET INOPATHY
Diabetic retinopathy is one of the most prevalent but  
preventable causes of blindness in the U.S. Complications 
from diabetic retinopathy can be largely prevented by  
glycemic and blood pressure control, as well as by early 
detection and timely treatment of diabetic retinopathy. 
Unfortunately, only about half of all patients with diabetes 
receive the recommended screening for retinopathy and 
only 40% of patients who require vision-preserving laser 
surgery receive it.20, 21  
No changes have been made to the recommendations for 
retinopathy screening and treatment.
Retinal photography may be indicated for examination  
of the retina in patients with diabetes in whom symptoms  
of visual disturbances may be present and in whom retinal  
examination may be unremarkable. However, retinal  
photography should not replace a comprehensive eye exam. 
Ocular conditions such as cataracts, hypertensive retinopathy, 
and glaucoma are optimally evaluated during a comprehensive 
eye exam. 
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Recommendations for Neuropathy Screening
•	 	Patients	with	diabetes	should	be	screened	for	presenting	signs	and	symptoms	of	diabetic	autonomic	neuropathy	
as part of the initial history and review of systems. (B)
•	 	Screening	for	signs	and	symptoms	of	cardiovascular	autonomic	neuropathy	should	be	instituted	at	diagnosis	 
of type 2 diabetes and five years after the diagnosis of type 1 diabetes. (E)
•	 	Conduct	a	comprehensive	foot	exam	at	least	annually.	The	exam	may	take	place	in	the	primary	care	setting	 
and	should	include	a	visual	inspection	and	palpation	for	pulses	as	well	as	a	sensory	evaluation	using	a	tuning	fork	
or	a	Semmes-Weinstein	monofilament.	(B)
•	 Perform	a	visual	foot	inspection	at	every	visit	for	patients	who	have	neuropathy.	(E)
•	 	Provide	self-care	education	to	all	patients,	especially	those	with	risk	factors	such	as	smoking	or	prior	lower	 
extremity	complications.	(B)
•	 	Refer	patients	who	have	loss	of	protective	sensation	and	structural	abnormalities,	or	who	have	a	prior	history	 
of	lower-extremity	complications,	to	a	podiatrist	for	ongoing	preventive	care.	(C) 
•	 	Screen	for	peripheral	artery	disease	(PAD)	by	assessing	the	pedal	pulses	and	evaluating	for	a	history	of	 
claudication.	Consider	obtaining	an	ankle-brachial	index	(ABI),	as	many	patients	with	PAD	are	asymptomatic.	(C)
•	 Refer	patients	with	significant	claudication	or	a	positive	ABI	for	further	vascular	assessment.	(C)
•	 Offer	a	multidisciplinary	approach	for	patients	with	foot	ulcers	and	high-risk	feet.	(B)
XI I I .   NEUROPATHY 
No changes have been made to the recommendations  
for neuropathy screening. See the 2009 Adult Diabetes  
Guidelines for signs and symptoms of autonomic  
neuropathy and for treatment recommendations. 
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XV.   IMMUNIZAT IONS
No changes have been made to the recommendations  
for immunizations.
In addition to influenza and pneumococcal vaccines, early 
vaccination against hepatitis B is indicated in patients likely 
to progress to end-stage kidney disease.  
Zoster vaccine was recently recommended by the Advisory 
Committee on Immunization Practices (ACIP) to reduce 
the risk of shingles and its associated pain in people > 60 
years of age.
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XIV.   PER IODO NTAL  D IS E AS E
No changes have been made to the recommendations for 
the management of periodontal disease. 
Recommendations for the Management of Periodontal Disease
Recommendations for Immunizations
•	 Conduct	an	oral	exam	as	part	of	the	yearly	comprehensive	visit.	(E)
•	 Advise	patients	of	the	importance	of	oral	hygiene.	(E)
•	 Promptly	refer	patients	with	symptoms	of	periodontal	disease	for	dental	evaluation.	(E)
•	 Encourage	patients	to	receive	dental	follow-up	twice	a	year	and	more	often	if	necessary.	(E)
•	 Encourage	patients	who	smoke	to	stop.	(A)
•	 Provide	an	influenza	vaccine	annually	to	all	patients	with	diabetes	>	6	months	of	age.	(C)
•	 	Administer	pneumococcal	polysaccharide	vaccine	to	all	patients	with	diabetes	>	2	years	of	age.	A	one-time	 
revaccination	is	recommended	for	individuals	>	65	years	of	age	previously	immunized	when	they	were	 
<	65	years	of	age	if	the	vaccine	was	administered	>	5	years	ago.	Other	indications	for	repeat	vaccination	 
include nephrotic syndrome, chronic renal disease, and other immunocompromised states. (C)
Recommendations for Psychosocial Assessment
•	 	Incorporate	psychological	screening	and	treatment	into	routine	care	rather	than	waiting	for	identification	 
of a specific problem or deterioration in psychological status. (E)
•	 	Psychosocial	screening	and	follow-up	should	include,	but	is	not	limited	to,	attitudes	about	the	illness;	 
expectations	for	medical	management	and	outcomes;	affect/mood;	general	and	diabetes-related	quality	 
of	life;	resources	(financial,	social,	and	emotional);	and	psychiatric	history.	(E)
•	 	Screen	for	psychosocial	problems	such	as	depression,	anxiety,	eating	disorders,	and	cognitive	impairment	 
when adherence to the medical regimen is poor. (E)
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XVI .   PSYCHOS OC IAL  ASS E SS MENT
No changes have been made to the recommendations for 
psychosocial assessment.  
It is widely believed that the use of second-generation  
antipsychotics (SGAs), also commonly known as atypical 
antipsychotics, is associated with an increased risk of  
diabetes.22, 23 What is less clear is whether the risk is indirect 
due to weight gain, or whether the SGAs directly affect  
insulin secretion or sensitivity.24 Additionally, different 
SGAs appear to have different degrees of effect on weight 
gain and insulin sensitivity.25 
In 2009, the European Psychiatric Association issued a  
position statement that while the use of SGAs is clearly  
associated with an increased risk of diabetes, the risk is small 
compared to traditional risk factors.26 Until further evidence 
is available, the position of the Work Group is that people 
who take SGAs should be considered to be at increased risk, 
and screened for diabetes according to standard guidelines.
Recommendations for Inpatient Glucose Management
•	 All	hospitalized	patients	with	diabetes	should	have	their	diabetes	clearly	identified	in	the	hospital	record.	(E)
•	 	All	patients	with	diabetes	should	have	an	order	for	blood	glucose	monitoring,	with	results	available	to	all	 
members of the health care team. (E)
•	 	Scheduled	prandial	insulin	doses	should	be	appropriately	timed	in	relation	to	meals	and	should	be	adjusted	to	
point-of-care	glucose	levels.	(C)
•	 	For	critically	ill	patients,	insulin	therapy	should	be	initiated	for	treatment	of	persistent	hyperglycemia	starting	 
at	a	threshold	of	no	greater	than	180	mg/dl.	Once	insulin	therapy	is	started,	target	glucose	levels	between	 
140–180	mg/dl	for	the	majority	of	patients.	(A) 
•	 	For	non-critically	ill	patients	treated	with	insulin,	premeal	blood	glucose	target	should	be	<	140	mg/dl	in	 
conjunction	with	random	blood	glucose	values	<	180	mg/dl,	provided	these	targets	can	be	safely	achieved.	(A)
XVI I .   INPAT IE NT  G LU COS E  MAN AGEMENT 
The recommendations have been revised to include initiation  
of insulin and target glucose levels for critically ill patients. 
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